Abstract: . . .  for Paget-Schroetter syn- drome. Ann Vasc Surg. 2001;15:3742. 11. Chang R, Horne MK, Mayo DJ, et al. Pulse- spray treatment of subclavian and jugular ve- nous thrombi with recombinant tissue plas- minogen activator. J Vasc Interv Radiol. 1996; 7:845851. 12. Adelman MA, Stone DH, Riles TS, et al. A mul- tidisciplinary approach to the treatment of Pag- et-Schroetter syndrome. Ann Vasc Surg. 1997; 11:149154. 13. Semba CP. Venous thrombolysis in the post- urokinase era. Tech Vasc Interv Radiol. 2000;3: 211. 14. Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. J Vasc Interv Radiol. 2000;11:411420. 15. Benenati J, Shlansky-Goldberg . . .
. . .  percutaneous angioplasty, stent, and surgery. Semin Vasc Surg. 1998;11:9195. 9. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis . J Am Coll Cardiol. 2000;36:13361343. 10. Angle N, Gelabert HA, Farooq MM, et al. Safety Page 6 738 AXILLOSUBCLAVIAN DVT Arko et al. J ENDOVASC THER 2003;10:733738 and efficacy of early surgical decompression of the thoracic outlet for Paget-Schroetter syn- drome. Ann Vasc Surg. 2001;15:3742. 11. Chang R, Horne MK, Mayo DJ, et al. Pulse- spray treatment of subclavian and jugular ve- nous thrombi with recombinant tissue plas- . . .
. . .  72:548550. 6. Gloviczki P, Kazmier FJ, Hollier LH. Axillary- subclavian venous occlusion: the morbidity of a nonlethal disease. J Vasc Surg. 1986;4:333 337. 7. Ellis MH, Manor Y, Witz M. Risk factors and management of patients with upper limb deep vein thrombosis . Chest. 2000;117:4346. 8. Rutherford RB. Primary subclavian-axillary vein thrombosis : the relative roles of throm- bolysis, percutaneous angioplasty, stent, and surgery. Semin Vasc Surg. 1998;11:9195. 9. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis . J Am Coll Cardiol. 2000;36:13361343. 10. Angle N, Gelabert HA, Farooq MM, et al. . . .
. . .  2003;10:733738 tions, including intracranial hemorrhage, can complicate lytic therapy when prolonged in- fusion of the drug is necessary. Thrombolysis in the management of axillosubclavian vein thrombosis with tissue plasminogen activator (tPA) requires between 12 and 24 hours at a rate of 0.5 mg/h. 14 We describe a novel technique for rapid thrombolysis in axillosubclavian vein throm- bosis using minimal thrombolytic agent. Fur- thermore, patency is restored at a single setting, avoiding multiple trips to the angi- ography suite. The technique utilizes a per- cutaneous mechanical thrombectomy device for rapid clot removal followed by low-dose localized . . .
--3000,4,375,3307,19916